Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. Chief Executive Officer and director John D. Quisel reported option-related trades on July 13, 2026. He exercised stock options for 33,000 shares of common stock at strike prices of $13.50 and $9.86, and sold 33,000 shares in open-market transactions at weighted-average prices of $76.0520, $74.9469 and $74.2729, with individual trades ranging from $73.62 to $76.29. These sales were made under a Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transactions, he holds 226,064 common shares directly and retains stock options covering 124,586 and 15,791 underlying shares.
Ironwood Pharmaceuticals filed to sell common stock through Morgan Stanley Smith Barney LLC. The filing covers 33,000 shares of common stock with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ. The shares are tied to an exercise of stock options for cash. The disclosure also notes prior Rule 10b5-1 sales for John Quisel of 34,000 shares of common stock on June 18, 2026 for proceeds of $2,387,296.40.
Disc Medicine, Inc. Chief Operating Officer Jonathan Yen-Wen Yu reported an option exercise and related stock sale. On July 7, 2026, he exercised stock options for 100 shares of common stock at $13.50 per share and sold 100 shares of common stock at an average price of $82.50 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 54,324 shares of common stock directly and 23,747 stock options exercisable for common shares, with the option grant vesting in 48 equal monthly installments after December 29, 2022.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting the proposed sale of 10,000 common shares on 07/07/2026 tied to an exercise of stock options for cash. The filing lists recent 10b5-1 sales by Jonathan Yu: 300 shares on 06/26/2026 for $21,750, 9,700 shares on 06/22/2026 for $704,795.21, and 18,612 shares on 06/16/2026 for $1,287,800.28.
Disc Medicine, Inc. Chief Legal Officer Rahul Khara exercised stock options and sold common shares in a pre-planned set of transactions. He exercised options for 2,500 shares of common stock at $14.69 per share and sold 2,500 shares at $75.00 per share. After these trades, he directly holds 52,173 common shares. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026, indicating they were pre-arranged rather than timed discretionarily.
Disc Medicine Chief Operating Officer Jonathan Yu reported a small, pre-planned insider transaction in Disc Medicine, Inc. common stock. On June 26, 2026, he exercised stock options to acquire 300 shares of common stock at $13.50 per share, then sold 300 shares of common stock at an average price of $72.50 per share in an open-market transaction.
The filing notes these trades were executed under a previously adopted Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily. A related footnote explains that the option grant vests in 48 equal monthly installments starting from December 29, 2022, contingent on Yu’s continued service.
Disc Medicine amended its existing Loan and Security Agreement with Hercules Capital to extend access to debt financing and adjust covenant timing. On June 25, 2026, the company agreed to immediately draw $30,000,000 from the Tranche 1-B Advance.
The prior $50,000,000 Tranche 1-C was restructured into a $25,000,000 loan available at the company’s option through March 31, 2027 and a separate $25,000,000 Tranche 1-D available through April 30, 2027. Draw periods for Tranche 2 and Tranche 3 were also extended to December 15, 2027 and June 30, 2028, respectively, and the parties set an initial testing date of July 1, 2028 for the amended minimum cash covenant.
Form 144 notice for IRON: proposed sale of 2,500 common shares via option exercise. The filing lists an intended disposition of 2,500 shares on 06/26/2026 described as an Exercise of Stock Options with $175,400.00 shown in the row. The filing also records prior 10b5-1 sales by Rahul Khara of 7,500 shares on 06/18/2026 for $526,660.50. Broker information shown: Morgan Stanley Smith Barney LLC, New York.
Disc Medicine, Inc. Chief Operating Officer Jonathan Yu Yen-Wen executed an options-related trade involving company stock. He exercised stock options to acquire 9,700 shares of common stock at $13.50 per share, then sold 9,700 shares in an open-market transaction at a weighted average price of $72.6593 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026. Following these trades, he directly holds 54,324 shares of common stock and 24,147 stock options that are scheduled to vest monthly through December 29, 2026 and expire on December 28, 2032.
Disc Medicine, Inc. held its 2026 annual meeting of stockholders on June 18, 2026. Stockholders elected three Class III directors — Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D. — each for a three-year term ending at the 2029 annual meeting.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, indicating overall support for current pay practices. In addition, they ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.